Frequency of polymorphisms in AML and control populations
| Polymorphism . | Controls . | Patients with AML . | Patients with t-AML . |
|---|---|---|---|
| XRCC1-399 | 178 | 133 | 34 |
| Arg/Arg | 55 (30.9) | 52 (39.1) | 18 (52.9) |
| Arg/Gln | 76 (42.7) | 57 (42.9) | 12 (35.3) |
| Gln/Gln | 47 (26.4) | 24 (18.0) | 4 (11.8) |
| P on χ2* | .15 | .03 | |
| Arg/Arg | 55 (30.9) | 52 (39.1) | 18 (52.9) |
| Arg/Gln + Gln/Gln | 123 (69.1) | 81 (60.9) | 16 (47.1) |
| Pon χ2* | .13 | .01 | |
| XRCC3-241 | 175 | 123 | 31 |
| Thr/Thr | 92 (52.6) | 53 (43.1) | 12 (38.7) |
| Thr/Met | 64 (36.6) | 53 (43.1) | 12 (38.7) |
| Met/Met | 19 (10.9) | 17 (13.8) | 7 (22.6) |
| P on χ2* | .27 | .14 | |
| Thr/Thr | 92 (52.6) | 53 (43.1) | 12 (38.7) |
| Thr/Met + Met/Met | 83 (47.4) | 70 (56.9) | 19 (61.3) |
| P on χ2* | .11 | .16 | |
| NQO1 | 175 | 134 | 33 |
| Pro/Pro | 110 (62.9) | 95 (70.9) | 19 (57.6) |
| Pro/Ser | 53 (30.3) | 30 (22.4) | 14 (42.4) |
| Ser/Ser | 12 (6.9) | 9 (6.7) | 0 (0) |
| P on χ2* | .29 | .16 | |
| Pro/Pro | 110 (62.9) | 95 (70.9) | 19 (57.6) |
| Pro/Ser + Ser/Ser | 65 (37.1) | 39 (29.1) | 14 (42.4) |
| Pon χ2* | .14 | .57 | |
| XRCC1-194 | 87 | 112 | 14 |
| Arg/Arg | 78 (89.7) | 100 (89.3) | 12 (85.7) |
| Arg/Trp | 7 (8.0) | 12 (10.7) | 2 (14.3) |
| Trp/Trp | 2 (2.3) | 0 (0) | 0 (0) |
| P on χ2* | .23 | .65 | |
| Arg/Arg | 78 (89.7) | 100 (89.3) | 12 (85.7) |
| Arg/Trp + Trp/Trp | 9 (10.3) | 12 (10.7) | 2 (14.3) |
| P on χ2* | .93 | .66 | |
| XPD-751 | 73 | 107 | 15 |
| Lys/Lys | 30 (41.1) | 40 (37.4) | 4 (26.7) |
| Lys/Gln | 32 (43.8) | 51 (47.7) | 8 (53.3) |
| Gln/Gln | 11 (15.1) | 16 (15.0) | 3 (20) |
| Pon χ2* | .86 | .58 | |
| Lys/Lys | 30 (41.1) | 40 (37.4) | 4 (26.7) |
| Lys/Gln + Gln/Gln | 43 (58.9) | 67 (62.6) | 11 (73.3) |
| P on χ2* | .62 | .30 |
| Polymorphism . | Controls . | Patients with AML . | Patients with t-AML . |
|---|---|---|---|
| XRCC1-399 | 178 | 133 | 34 |
| Arg/Arg | 55 (30.9) | 52 (39.1) | 18 (52.9) |
| Arg/Gln | 76 (42.7) | 57 (42.9) | 12 (35.3) |
| Gln/Gln | 47 (26.4) | 24 (18.0) | 4 (11.8) |
| P on χ2* | .15 | .03 | |
| Arg/Arg | 55 (30.9) | 52 (39.1) | 18 (52.9) |
| Arg/Gln + Gln/Gln | 123 (69.1) | 81 (60.9) | 16 (47.1) |
| Pon χ2* | .13 | .01 | |
| XRCC3-241 | 175 | 123 | 31 |
| Thr/Thr | 92 (52.6) | 53 (43.1) | 12 (38.7) |
| Thr/Met | 64 (36.6) | 53 (43.1) | 12 (38.7) |
| Met/Met | 19 (10.9) | 17 (13.8) | 7 (22.6) |
| P on χ2* | .27 | .14 | |
| Thr/Thr | 92 (52.6) | 53 (43.1) | 12 (38.7) |
| Thr/Met + Met/Met | 83 (47.4) | 70 (56.9) | 19 (61.3) |
| P on χ2* | .11 | .16 | |
| NQO1 | 175 | 134 | 33 |
| Pro/Pro | 110 (62.9) | 95 (70.9) | 19 (57.6) |
| Pro/Ser | 53 (30.3) | 30 (22.4) | 14 (42.4) |
| Ser/Ser | 12 (6.9) | 9 (6.7) | 0 (0) |
| P on χ2* | .29 | .16 | |
| Pro/Pro | 110 (62.9) | 95 (70.9) | 19 (57.6) |
| Pro/Ser + Ser/Ser | 65 (37.1) | 39 (29.1) | 14 (42.4) |
| Pon χ2* | .14 | .57 | |
| XRCC1-194 | 87 | 112 | 14 |
| Arg/Arg | 78 (89.7) | 100 (89.3) | 12 (85.7) |
| Arg/Trp | 7 (8.0) | 12 (10.7) | 2 (14.3) |
| Trp/Trp | 2 (2.3) | 0 (0) | 0 (0) |
| P on χ2* | .23 | .65 | |
| Arg/Arg | 78 (89.7) | 100 (89.3) | 12 (85.7) |
| Arg/Trp + Trp/Trp | 9 (10.3) | 12 (10.7) | 2 (14.3) |
| P on χ2* | .93 | .66 | |
| XPD-751 | 73 | 107 | 15 |
| Lys/Lys | 30 (41.1) | 40 (37.4) | 4 (26.7) |
| Lys/Gln | 32 (43.8) | 51 (47.7) | 8 (53.3) |
| Gln/Gln | 11 (15.1) | 16 (15.0) | 3 (20) |
| Pon χ2* | .86 | .58 | |
| Lys/Lys | 30 (41.1) | 40 (37.4) | 4 (26.7) |
| Lys/Gln + Gln/Gln | 43 (58.9) | 67 (62.6) | 11 (73.3) |
| P on χ2* | .62 | .30 |
Values are numbers (%) of controls or patients unless otherwise indicated.
For comparisons between patients and controls.